From Molecule Strategy to Execution

Read the full article by Phanindra Venkata Gottipati | CEO, VirtuNx

Portfolio management and project management are often treated as neighboring disciplines. Strategy teams evaluate opportunities and recommend priorities. Project teams translate approved choices into milestones, tasks, dependencies and delivery plans. Both groups may perform their work well, yet the transition between them remains one of the most fragile points in pharmaceutical execution.

A portfolio decision changes more than status. It changes resource expectations, risk appetite, timing, governance attention and the assumptions under which a development plan should proceed. When those implications are transferred through presentations, spreadsheets and meetings, important context can be diluted. The project may continue to report activity without reflecting the strategic reason it exists, or the conditions under which leadership would reconsider it.

The reverse problem is equally important. Execution produces new evidence every day. A technical delay, sourcing constraint, regulatory question, IP development or cost change may alter the attractiveness of the molecule. If that information remains inside project-level reporting, portfolio leaders may continue evaluating the asset using assumptions that are no longer current.

Closing this gap requires a connected operating model. The molecule should remain the common thread from evaluation through execution. Portfolio criteria, decision rationale and key assumptions should flow into the development plan. Stage gates should define the evidence required for the next commitment. Risks and issues should be connected to the milestones, decisions and value drivers they may affect. Project progress should update the portfolio view without requiring teams to rebuild the story for every leadership review.

This does not mean placing every activity into one oversized workflow. Different teams need different views and working patterns. Strategy leaders need comparisons, scenarios and decision history. R&D and functional teams need technical workplans. Project leaders need dependencies, ownership and intervention signals. Executives need material exceptions and choices. The operating model should preserve these differences while keeping the underlying context connected.

A connected approach also improves governance. When a milestone becomes at risk, the system can show not only that it is late but why the delay matters. When a stage gate is reviewed, the evidence and open conditions are visible. When leadership changes a priority, the affected plans and owners can be identified. This reduces the time spent reconciling versions and increases the time available for judgment and action.

PortiVix is designed around this portfolio-to-execution continuum: molecule-centered planning, portfolio structures, stage gates, project templates, milestones, tasks, risks, issues, collaboration and management reporting within a common governance context. The goal is not to replace expert work with software. It is to prevent strategic context from being lost as work moves across functions and time.

Pharma organizations do not create value by making a good portfolio decision once. They create value by repeatedly carrying the intent of that decision through development, and by bringing execution evidence back into the next strategic choice.

Can your leadership trace a molecule from the original investment rationale to its current milestones, risks and next decision point without reconstructing the story manually?

Let us know in the comments below.